Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

ADUHELM®

Our center is aware of the approval, on June 7th, by the Food and Drug Administration (FDA) of the medication aducanumab (brand name ADUHELM®) to treat Alzheimer’s disease (see FDA.gov). Aducanumab is the first drug approved in the United States, which removes Alzheimer’s disease proteins from the brain, and is designed to slow the progression of Alzheimer’s disease. We are waiting for more information on availability and eligibility for insurance coverage, including Medicare. This is an evolving situation which we are monitoring very closely, and we are working towards offering it here soon.

You may schedule a visit with your doctor to discuss this drug with you. If you are a new patient, you will first need to schedule an initial evaluation and diagnostic testing to determine potential eligibility.

Welcome

The Taub Institute for Research on Alzheimer's Disease and the Aging Brain is the nucleus of a dynamic, multidisciplinary endeavor.

The Institute brings together Columbia University researchers and clinicians to uncover the causes of Alzheimer's, Parkinson's and other age-related brain diseases and to discover ways to prevent and cure these diseases

Directors: Richard Mayeux, MD, MS, and
Michael Shelanski, MD, PhD
Deputy Directors: Philip De Jager, PhD, MD, MMSc and Rafael A. Lantigua, MD

The Taub Institute for Research on Alzheimer's Disease and the Aging Brain
Make an Appointment
Donate